Discovery of a novel oral, non-RGD pan-αv integrin inhibitor for castration resistant prostate cancer treatment

被引：0
作者：
Gu, Yanlun [1 ,4 ]
Sun, Xiaojiao [2 ]
Dong, Bingqi [3 ]
Song, Song [2 ]
Liu, Zhenming [2 ]
Pang, Xiaocong [1 ,4 ]
Cui, Yimin [1 ,4 ]
机构：
[1] Peking Univ First Hosp, Dept Pharm, Beijing, Peoples R China
[2] Peking Univ, Sch Pharmaceut Sci, Beijing, Peoples R China
[3] Peking Univ First Hosp, Dept Gen Surg, Beijing, Peoples R China
[4] Peking Univ, Inst Clin Pharmacol, Beijing, Peoples R China
来源：
BRITISH JOURNAL OF PHARMACOLOGY | 2023年 / 180卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P0651
引用
收藏
页码：508 / 509
页数：2
相关论文
共 50 条
  • [31] Physician preferences for non-metastatic castration-resistant prostate cancer treatment
    Sandy Srinivas
    Ateesha F. Mohamed
    Sreevalsa Appukkuttan
    Marc Botteman
    Xinyi Ng
    Namita Joshi
    Erica Horodniceanu
    A. Reginald Waldeck
    Stacey J Simmons
    BMC Urology, 20
  • [32] Discovery of Androgen Metabolism Enhancing Androgen Receptor Antagonists for the Treatment of Castration-Resistant prostate Cancer
    Narayanan, R.
    Effah, W.
    Ponnusamy, S.
    Hwang, D. J.
    Miller, D.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S88 - S89
  • [33] The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer
    Darne, Chetan Padmakar
    Velaparthi, Upender
    Saulnier, Mark
    Frennesson, David
    Liu, Peiying
    Huang, Audris
    Tokarski, John
    Fura, Aberra
    Spires, Thomas
    Newitt, John
    Spires, Vanessa M.
    Obermeier, Mary T.
    Elzinga, Paul A.
    Gottardis, Marco M.
    Jayaraman, Lata
    Vite, Gregory D.
    Balog, Aaron
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2022, 75
  • [34] Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer
    Maughan, Benjamin L.
    Suzman, Daniel L.
    Luber, Brandon
    Wang, Hao
    Glavaris, Stephanie
    Hughes, Robert
    Sullivan, Rana
    Harb, Rana
    Boudadi, Karim
    Paller, Channing
    Eisenberger, Mario
    Demarzo, Angelo
    Ross, Ashely
    Antonarakis, Emmanuel S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (06) : 1297 - 1304
  • [35] Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer
    Benjamin L. Maughan
    Daniel L. Suzman
    Brandon Luber
    Hao Wang
    Stephanie Glavaris
    Robert Hughes
    Rana Sullivan
    Rana Harb
    Karim Boudadi
    Channing Paller
    Mario Eisenberger
    Angelo Demarzo
    Ashely Ross
    Emmanuel S. Antonarakis
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 1297 - 1304
  • [36] Discovery of the First-in-Class RORγ Covalent Inhibitors for Treatment of Castration-Resistant Prostate Cancer
    Fang, Wei
    Zheng, Jianwei
    Deng, Lin
    An, Yana
    Rong, Deqin
    Wei, Jianwei
    Xiong, Xiao-Feng
    Wang, Junjian
    Wang, Yuanxiang
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (02) : 1481 - 1499
  • [37] ODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration-resistant prostate cancer
    Oksala, R.
    Karimaa, M.
    Ramela, M.
    Riikonen, R.
    Huhtaniemi, R.
    Rummakko, P.
    Wohlfahrt, G.
    Vuorela, A.
    Mustonen, M. V.
    Kallio, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [38] A novel small molecule inhibitor of p300/CBP for the treatment of castration-resistant prostate cancer: Preclinical evaluation.
    Brooks, Nigel
    Pegg, Neil
    Worthington, Jenny
    Young, Barbara
    Prosser, Amy
    Lane, Jordan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [39] Discovery of a novel series of androgen receptor antagonists with potential therapeutic applications in castration-resistant prostate cancer
    Li, Huifang
    Hassona, Mohamed D. H.
    Lack, Nathan A.
    Axerio-Cilies, Peter
    Leblanc, Eric
    Guns, Emma T.
    Rennie, Paul S.
    Cherkasov, Artem
    CANCER RESEARCH, 2014, 74 (19)
  • [40] New Treatment Option - Apalutamide for non-metastatic, castration-resistant Prostate Cancer
    Hadaschik, B.
    Panic, A.
    UROLOGE, 2018, 57 (06): : 729 - 730
12345